Status: Recruiting
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Participants needed: 28
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Wake Forest University Health SciencesUpdated: Mar 23, 2026Locations: 1
Eligibility criteria
Patients must have stage II or stage III NSCLC confirmed by histologic or cytolo... [+9]
Uncontrolled respiratory symptoms (i.e., cough, dyspnea, fevers, chest pain, or... [+6]